Did ASCO 2026 Deliver on Its Biggest Pre-Meeting Predictions?

Ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Sivraj Muralikrishnan, MD, a medical oncologist and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey, about which trials he was anticipating the most across pancreatic cancer, lung cancer, and head and neck cancer. Muralikrishnan highlighted the phase 3 RASolute 302 trial (NCT06625320) of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) as his standout pick, alongside the phase 3 LIBRETTO-432 trial (NCT04819100) of adjuvant selpercatinib (Retevmo) in RET fusion–positive non–small cell lung cancer (NSCLC) and the phase 3 HARMONi-6 trial (NCT05840016)comparing ivonescimab plus chemotherapy with tislelizumab (Tevimbra) plus chemotherapy in squamous NSCLC.^1-3 He also flagged 2 potential underdogs to watch: the phase 3b TRITON study (NCT06008093) of dual checkpoint blockade in STK11/KEAP1/KRAS-mutated NSCLC, and the 7-year update of the phase 3 CROWN trial (NCT03052608) of lorlatinib (Lorbrena) in ALK-positive NSCLC.^4-5